Dividends and bonus issues: 31 stocks turning ex-record date this week. Do you own any?As many as 31 companies, including HDFC Bank, Tata group firms and Brigade Enterprises, will turn ex-record date for dividends and bonus is...
14 Jun, 2026, 09.52 AM IST
IPO investors brace for 70 lock-in expiries worth $35 billion in three months. Do you own any?According to Nuvama Alternative & Quantitative Research, the Indian stock market is set to witness a significant wave of lock-in expiries b...
28 May, 2026, 03.20 PM IST
IPO investors brace for 73 lock-in expiries worth $34 billion in three months. Will your portfolio be impacted?India’s stock market is set for a wave of IPO lock-in expiries over the next three months, with shares worth $34 billion from 73 recently l...
20 May, 2026, 10.03 AM IST
Ahead of Market: 10 things that will decide stock market action on WednesdayIndian equity markets extended losses for a fourth straight session as broad-based selling in IT, banking, auto, and consumer stocks dragge...
12 May, 2026, 09.16 PM IST
Ahead of Market: 10 things that will decide stock market action on WednesdayIndian markets closed lower amid selling in financial, consumer and realty stocks, with Nifty and Sensex declining. Technical indicators si...
05 May, 2026, 09.31 PM IST
Corona Remedies shares climb 3% after blockbuster debut. What’s driving the post-listing surge?Corona Remedies shares rose sharply on December 15, extending gains after a blockbuster IPO debut. Strong institutional demand, consistent ...
15 Dec, 2025, 11.18 AM IST
Corona Remedies shares make strong start, list at 38% premium over IPO priceCorona Remedies Share Price: Corona Remedies debuted on Dalal Street with a significant 38.42% premium, opening at Rs 1,470 on NSE and Rs 1...
15 Dec, 2025, 10.21 AM IST
Corona Remedies and Wakefit Innovations to list tomorrow; GMP suggests sharp upside for pharma playCorona Remedies and Wakefit Innovations are set to list amid divergent grey market signals. Corona Remedies commands strong listing expecta...
14 Dec, 2025, 11.01 AM IST
How to check Corona Remedies IPO allotment on Bigshare Services as GMP stays strongCorona Remedies’ Rs 655-crore offer-for-sale IPO saw strong demand across investor categories, with overall subscription at 144.54 times an...
11 Dec, 2025, 11.35 AM IST
Corona Remedies IPO Day 3: Issue subscribed over 18.5x, GMP at 25%. Should you apply?Corona Remedies' Rs 655.37-crore IPO is in its final subscription day. Investors show strong interest, with the issue subscribed 18.54 time...
10 Dec, 2025, 03.10 PM IST
Corona Remedies IPO Day 2: Nearly 3x subscription so far; check GMP trends & should you apply?Corona Remedies’ Rs 655-crore IPO entered Day 2 after achieving 62% subscription on Day 1, driven largely by retail demand. The IPO’s grey ...
09 Dec, 2025, 12.46 PM IST
Corona Remedies IPO Day 1: Registers over 30% subscription, strong GMP, and key detailsCorona Remedies’ IPO opened with decent subscription demand, led by strong retail demand and a robust Rs 290 grey-market premium. The Rs 65...
08 Dec, 2025, 02.35 PM IST
Corona Remedies IPO: Check GMP, price band, review, subscription and other detailsCorona Remedies' IPO is now open for subscription. The company is offering shares at a price band of Rs 1,008 to Rs 1,062. The issue aims t...
08 Dec, 2025, 09.52 AM IST
Corona Remedies IPO opens next week: GMP among 10 things to know before subscriptionCorona Remedies is launching its Rs 655 crore IPO next week. The Gujarat-based pharmaceutical firm is offering 100% of its shares. The grey...
04 Dec, 2025, 11.30 AM IST
Pharma firm Corona Remedies IPO to open on Dec 8; sets price band at Rs 1,008-1,062/ sharePharma firm Corona Remedies, backed by ChrysCapital, has set its IPO price band at Rs 1,008-1,062, valuing the company at nearly Rs 6,500 c...
04 Dec, 2025, 10.43 AM IST
Corona Remedies files draft papers with Sebi for Rs 800 crore IPOCorona Remedies, an Indian pharmaceutical company, has filed preliminary documents with SEBI to launch an Rs 800-crore IPO. The IPO consist...
30 Apr, 2025, 09.56 PM IST
CCI approves Corona Remedies-GlaxoSmithKline dealDilo-BM, Dilo-DX, Stelbid and Vitneurin brands of GlaxoSmithKline would be acquired by Corona Remedies along with trademark and goodwill.
07 Mar, 2017, 11.13 PM IST